Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Executive Summary

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Register for our free email digests:


Click Here to Continue...